Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-03-21

FDA Approved: QULIPTA — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA approved a supplemental application for QULIPTA (atogepant) submitted by AbbVie.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Qulipta (atogepant)

Snippet

SUPPL AP for QULIPTA (ATOGEPANT)